Oritavancin on the Results of Multiple Coagulation Tests in Healthy Volunteers

Phase 1 Completed 20 enrolled Melinta Therapeutics, Inc. Christchurch Clinical Studies Trust Ltd · collab

NaSingle-groupOpen-labelOther

Summary

The study will determine the magnitude and duration (time to resolution i.e., returning to normal ranges) of elevations in the following coagulation test results after a single 1200 mg dose of oritavancin: Prothrombin Time/International Normalized Ratio (PT/INR), Activated clotting time (ACT), Activated Partial Thromboplastin Time (APTT), Chromogenic Factor Xa Assay, D-dimer, Silica Clot Time and Dilute Russell's Viper Venom Time (DRVVT).

Timeline

Start: 2015-01
Primary completion: 2015-03
Completion: 2015-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Oritavancin	Other / unclassified	1200 mg	Intravenous

Indications

No indication recorded.